» Articles » PMID: 33520872

Therapeutic Potential of Mesenchymal Stem Cells in Treating Both Types of Diabetes Mellitus and Associated Diseases

Overview
Specialty Endocrinology
Date 2021 Feb 1
PMID 33520872
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Diabetes mellitus is a common lifestyle disease which can be classified into type 1 diabetes mellitus and type 2 diabetes mellitus. While both result in hyperglycemia due to lack of insulin action and further associated chronic ailments, there is a marked distinction in the cause for each type due to which both require a different prophylaxis. As observed, type 1 diabetes is caused due to the autoimmune action of the body resulting in the destruction of pancreatic islet cells. On the other hand, type 2 diabetes is caused either due to insulin resistance of target cells or lack of insulin production as per physiological requirements. Attempts to cure the disease have been made by bringing drastic changes in the patients' lifestyle; parenteral administration of insulin; prescription of drugs such as biguanides, meglitinides, and amylin; pancreatic transplantation; and immunotherapy. While these attempts cause a certain degree of relief to the patient, none of these can cure diabetes mellitus. However, a new treatment strategy led by the discovery of mesenchymal stem cells and their unique immunomodulatory and multipotent properties has inspired therapies to treat diabetes by essentially reversing the conditions causing the disease. The current review aims to enumerate the role of various mesenchymal stem cells and the different approaches to treat both types of diabetes and its associated diseases as well.

Citing Articles

Advanced therapy to cure diabetes: mission impossible is now possible?.

Rohban R, Martins C, Esni F Front Cell Dev Biol. 2024; 12:1484859.

PMID: 39629270 PMC: 11611888. DOI: 10.3389/fcell.2024.1484859.


The effect of diabetes mellitus on differentiation of mesenchymal stem cells into insulin-producing cells.

Badr O, Kamal M, El-Maraghy S, Ghaiad H Biol Res. 2024; 57(1):20.

PMID: 38698488 PMC: 11067316. DOI: 10.1186/s40659-024-00502-4.


Micro RNA based MSC EV engineering: Targeting the BMP2 cascade for bone repair.

Huang C, Kang M, Leung K, Lu Y, Shirazi S, Gajendrareddy P Front Cell Dev Biol. 2023; 11:1127594.

PMID: 36846585 PMC: 9945088. DOI: 10.3389/fcell.2023.1127594.

References
1.
Shomali M . Diabetes treatment in 2025: can scientific advances keep pace with prevalence?. Ther Adv Endocrinol Metab. 2012; 3(5):163-73. PMC: 3498849. DOI: 10.1177/2042018812465639. View

2.
Kern S, Eichler H, Stoeve J, Kluter H, Bieback K . Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006; 24(5):1294-301. DOI: 10.1634/stemcells.2005-0342. View

3.
Kong D, Zhuang X, Wang D, Qu H, Jiang Y, Li X . Umbilical cord mesenchymal stem cell transfusion ameliorated hyperglycemia in patients with type 2 diabetes mellitus. Clin Lab. 2015; 60(12):1969-76. DOI: 10.7754/clin.lab.2014.140305. View

4.
Madeira C, Santhagunam A, Salgueiro J, Cabral J . Advanced cell therapies for articular cartilage regeneration. Trends Biotechnol. 2014; 33(1):35-42. DOI: 10.1016/j.tibtech.2014.11.003. View

5.
Tiwari P . Recent Trends in Therapeutic Approaches for Diabetes Management: A Comprehensive Update. J Diabetes Res. 2015; 2015:340838. PMC: 4530263. DOI: 10.1155/2015/340838. View